Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58

被引：0
|
作者：
Zelniker, T. A. [1 ,2 ]
Raz, I. [3 ]
Mosenzon, O. [3 ]
Dwyer, J. P. [4 ]
Heerspink, H. J. L. [5 ]
Cahn, A. [3 ]
Im, K. [1 ,2 ]
Bhatt, D. L. [1 ,2 ]
Leiter, L. A. [6 ]
McGuire, D. K. [7 ]
Wilding, J. P. H. [8 ]
Gause-Nilsson, I. A. M. [9 ]
Langkilde, A. M. [9 ]
Sabatine, M. S. [1 ,2 ]
Wiviott, S. D. [1 ,2 ]
机构：
[1] Brigham & Womens Hosp, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Hadassah Univ, Med Ctr, Jerusalem, Israel
[4] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA
[5] Univ Med Ctr Groningen, Groningen, Netherlands
[6] Univ Toronto, Toronto, ON, Canada
[7] Univ Texas Southwestern Med Sch, Dallas, TX USA
[8] Univ Liverpool, Liverpool, Merseyside, England
[9] AstraZeneca, Gothenburg, Sweden
来源：
EUROPEAN HEART JOURNAL | 2019年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
192
引用
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [31] DAPAGLIFLOZIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND PRIOR MYOCARDIAL INFARCTION: A SUB-ANALYSIS FROM DECLARE TIMI-58 TRIAL
    Furtado, Remo Holanda de Mendonca
    Bonaca, Marc
    Raz, Itamar
    Zelniker, Thomas
    Mosenzon, Ofri
    Cahn, Avivit
    Kuder, Julia
    Murphy, Sabina
    Bhatt, Deepak L.
    Leiter, Lawrence
    McGuire, Darren
    Wilding, John P. H.
    Ruff, Christian
    Gause-Nilsson, Ingrid A. M.
    Fredriksson, Martin
    Langkilde, Anna Maria
    Sabatine, Marc
    Wiviott, Stephen
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 1 - 1
  • [32] Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study
    Carlos Escobar
    Cristóbal Morales
    Margarita Capel
    Susana Simón
    Ferran Pérez-Alcántara
    Elisenda Pomares
    BMC Health Services Research, 22
  • [33] Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study
    Escobar, Carlos
    Morales, Cristobal
    Capel, Margarita
    Simon, Susana
    Perez-Alcantara, Ferran
    Pomares, Elisenda
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [34] EFFECTS OF DAPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS BODY MASS INDEX CATEGORIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN THE DECLARE TIMI 58 TRIAL
    Oyama, Kazuma
    Raz, Itamar
    Cahn, Avivit
    Kuder, Julia
    Murphy, Sabina
    Bhatt, Deepak
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John
    Park, Kyong-Soo
    Goudev, Assen
    Diaz, Rafael
    Spinar, Jindrich
    Gause-Nilsson, Ingrid
    Mosenzon, Ofri
    Sabatine, Marc
    Wiviott, Stephen D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 660 - 660
  • [35] Cardiorenal and metabolic outcomes of dapagliflozin vs placebo in patients at high cardiovascular risk without established cardiovascular disease: analyses from the DECLARE-TIMI 58 study
    Cahn, A.
    Raz, I.
    Leiter, L. A.
    Mosenzon, O.
    Murphy, S. A.
    Bhatt, D. L.
    McGuire, D. K.
    Wilding, J. P. H.
    Gause-Nilsson, I. A. M.
    Langkilde, A.
    Sabatine, M.
    Wiviott, S. D.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S269 - S269
  • [36] Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: a patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials
    Moura, F.
    Wiviott, S.
    Chertow, G.
    Dwyer, J.
    Gause-Nilsson, I
    Johansson, P.
    Langkilde, A.
    McMurray, J.
    Mosenzon, O.
    Raz, I
    Rossing, P.
    Wheeler, D.
    Sabatine, M.
    Heerspink, H.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2407 - 2407
  • [37] Clinical Features and C-Peptide Levels Associated with Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Dapagliflozin vs. Placebo-Insights from DECLARE-TIMI 58
    Kang, Yu Mi
    Melloni, Giorgio E. M.
    Cahn, Avivit
    Raz, Itamar
    Moura, Filipe
    Bhatt, Deepak L.
    Inzucchi, Silvio E.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John
    Gause-Nilsson, Ingrid A.
    Oscarsson, Jan
    Marston, Nicholas
    Ruff, Christian T.
    Sabatine, Marc S.
    Wiviott, Stephen D.
    DIABETES, 2024, 73
  • [38] Dapagliflozin vermindert das Risiko für Krankenhausaufenthalte von Typ-2-Diabetes-PatientenNeue Ergebnisse aus der DECLARE-TIMI 58-StudieDapagliflozin reduces the risk for hospitalization in patients with type 2 diabetesNew results from the DECLARE-TIMI 58 trial
    Imke Schamarek
    Die Diabetologie, 2023, 19 (5) : 702 - 704
  • [39] Dapagliflozin and Changes in Metabolic Syndrome in Patients With Type 2 Diabetes: A DECLARE TIMI 58 Sub-Analysis
    Moura, Filipe A.
    Raz, Itamar
    Cahn, Avivit
    Goodrich, Erica
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    Wilding, John
    Gause-nilsson, Ingrid A.
    Mosenzon, Ofri
    Sabatine, Marc S.
    Wiviott, Stephen D.
    CIRCULATION, 2021, 144
  • [40] Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial (vol 7, pg 606, 2019)
    Mosenzon, O.
    Wiviott, S. D.
    Cahn, A.
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (08): : E20 - E20
12345